Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
Top Cited Papers
- 3 November 2020
- journal article
- review article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 35 (S3) , 954-963
Abstract
Background Despite evidence that medications to treat opioid use disorder (OUD) are effective, most people who could benefit from this treatment do not receive it. This rapid review synthesizes evidence on current barriers and facilitators to buprenorphine/naloxone and naltrexone at the patient, provider, and system levels to inform future interventions aimed at expanding treatment. Methods We systematically searched numerous bibliographic databases through May 2020 and selected studies published since 2014. Study selection, data abstraction, coding of barriers and facilitators, and quality assessment were first completed by one reviewer and checked by a second. Results We included 40 studies of buprenorphine (5 also discussed naltrexone). Four types of patient and provider-level barriers to OUD medication use emerged—stigma related to OUD medications, treatment experiences and beliefs (positive or negative), logistical issues (time and costs as well as insurance and regulatory requirements), and knowledge (high or low) of OUD and the role of medications. Stigma was the most common barrier among patients, while logistical issues were the most common barriers among providers. Facilitators for both patients and providers included peer supports. Most administrator-identified or system-level barriers and facilitators fit into the category of logistical issues. We have moderate confidence in buprenorphine findings but low confidence in naltrexone findings due to the small number of studies. Discussion Stigma, treatment experiences, logistical issues, and knowledge gaps are the main barriers associated with low utilization of OUD medications. These barriers can overlap and mutually reinforce each other, but given that, it is plausible that reducing one barrier may lead to reductions in others. The highest priority for future research is to evaluate interventions to reduce stigma. Other priorities for future research include better identification of barriers and facilitators for specific populations, such as those with OUD related to prescription opioids, and for naltrexone use. Protocol Registration PROSPERO; CRD42019133394Keywords
Funding Information
- U.S. Department of Veterans Affairs
This publication has 41 references indexed in Scilit:
- Buprenorphine prescribing practice trends and attitudes among New York providersJournal of Substance Abuse Treatment, 2017
- Systemic and individual factors in the buprenorphine treatment-seeking process: a qualitative studySubstance Abuse Treatment, Prevention, and Policy, 2017
- Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013Substance Abuse, 2016
- Counselor Training and Attitudes toward Pharmacotherapies for Opioid Use DisorderSubstance Abuse, 2016
- Implementing buprenorphine in addiction treatment: payer and provider perspectives in OhioSubstance Abuse Treatment, Prevention, and Policy, 2015
- Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorderAddiction Science & Clinical Practice, 2015
- Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participantsJournal of Substance Abuse Treatment, 2015
- Barriers to Primary Care Physicians Prescribing BuprenorphineThe Annals of Family Medicine, 2014
- Determinants of buprenorphine treatment for opioid dependenceJournal of Substance Abuse Treatment, 2014
- Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.Psychology of Addictive Behaviors, 2011